/JAGX
JAGX Stock - Jaguar Health, Inc.
Healthcare|BiotechnologyNASDAQ
$1.17+3.54%
+$0.04 (+3.54%) • Dec 19
65
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.0
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+1009.4%upside
Target: $12.98
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for JAGX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$1.16 – $1.18
TARGET (TP)$12.98
STOP LOSS$1.08
RISK/REWARD1:131.2
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-0.10
52W High$33.25
52W Low$1.00
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $11.69M | $9.76M | $11.96M | $4.33M | $9.38M |
| Gross Profit | $9.73M | $7.72M | $9.94M | $2.00M | $6.11M |
| Gross Margin | 83.3% | 79.1% | 83.1% | 46.2% | 65.1% |
| Operating Income | $-30,831,000 | $-34,291,000 | $-34,415,000 | $-40,708,000 | $-26,647,000 |
| Net Income | $-38,492,000 | $-41,300,000 | $-47,454,000 | $-52,595,000 | $-33,809,000 |
| Net Margin | -329.3% | -423.1% | -396.9% | -1213.3% | -360.2% |
| EPS | $-130.69 | $-2685.00 | $-4070250.00 | $-11370375.00 | $-72299250.00 |
Company Overview
Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic, and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer for multiple possible follow-on indications, including cancer therapy-related diarrhea; orphan-drug indications for symptomatic relief of diarrhea in infants and children with congenital diarrheal disorders and for adult and pediatric patients for short bowel syndrome with intestinal failure with; supportive care for diarrhea relief in inflammatory bowel diseases; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, it develops lechlemer, a second-generation anti-secretory agent for cholera; and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. Jaguar Health, Inc. was founded in 2013 and is headquartered in San Francisco, California.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
JAGXBeat Rate
22%
Last 18 quarters
Avg Surprise
-274053.7%
EPS vs Estimate
Beats / Misses
4/14
Last 12 quarters
Latest EPS
$-6.28
Q4 2025
EPS Surprise History
Q2 24
+59.5%
$-594.64vs$-1470.00
Q2 24
-133.3%
$-90.36vs$-38.73
Q3 24
-8316.7%
$-101.00vs$-1.20
Q4 24
-1007.6%
$-26.25vs$-2.37
Q2 25
+98.2%
$-0.34vs$-18.50
Q2 25
+7.2%
$-16.70vs$-18.00
Q3 25
-102.0%
$-10.26vs$-5.08
Q4 25
-47.4%
$-6.28vs$-4.26
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 30, 2026 | — | — | — | — |
Q4 2025 | Nov 14, 2025 | $-4.26 | $-6.28 | -47.4% | ✗ MISS |
Q3 2025 | Aug 14, 2025 | $-5.08 | $-10.26 | -102.0% | ✗ MISS |
Q2 2025 | May 15, 2025 | $-18.00 | $-16.70 | +7.2% | ✓ BEAT |
Q2 2025 | Apr 7, 2025 | $-18.50 | $-0.34 | +98.2% | ✓ BEAT |
Q4 2024 | Nov 13, 2024 | $-2.37 | $-26.25 | -1007.6% | ✗ MISS |
Q3 2024 | Aug 13, 2024 | $-1.20 | $-101.00 | -8316.7% | ✗ MISS |
Q2 2024 | May 14, 2024 | $-38.73 | $-90.36 | -133.3% | ✗ MISS |
Q2 2024 | Apr 1, 2024 | $-1470.00 | $-594.64 | +59.5% | ✓ BEAT |
Q4 2023 | Nov 14, 2023 | $-1.23 | $-572.29 | -46427.6% | ✗ MISS |
Q3 2023 | Aug 14, 2023 | $-1.53 | $-632.53 | -41241.8% | ✗ MISS |
Q2 2023 | May 15, 2023 | $-6750.00 | $-3599.40 | +46.7% | ✓ BEAT |
Q2 2023 | Apr 28, 2023 | — | $-631128.85 | — | — |
Q4 2022 | Nov 14, 2022 | $-5.62 | $-13588.19 | -241682.7% | ✗ MISS |
Q3 2022 | Aug 22, 2022 | $-16.50 | $-13588.19 | -82252.7% | ✗ MISS |
Q2 2022 | May 10, 2022 | $-12.75 | $-45293.96 | -355146.7% | ✗ MISS |
Q1 2022 | Mar 11, 2022 | $-6.75 | $-35102.82 | -519941.8% | ✗ MISS |
Q4 2021 | Nov 17, 2021 | $-12.75 | $-30573.42 | -239691.5% | ✗ MISS |
Q3 2021 | Aug 13, 2021 | $-3.00 | $-33973.87 | -1132362.3% | ✗ MISS |
Q2 2021 | May 17, 2021 | $-1.50 | $-33973.87 | -2264824.7% | ✗ MISS |
Latest News
Jaguar Health's Napo Pharma's Independent Investigator At SBS-IF Treatment Institution Submits Abstract Describing Preliminary Findings From Clinical Trial Evaluating Oral Liquid Formulation Of Crofelemer In Adult SBS-IF Patients
➖ NeutralBenzinga•Dec 15, 2025, 02:07 PM
FDA Approves Renewal Of Canalevia-CA1
📈 PositiveBenzinga•Dec 10, 2025, 02:05 PM
Jaguar Health Secures FDA Conditional Approval Extension For Canalevia-CA1 To Treat Canine Chemotherapy-Induced Diarrhea Through December 2026
📈 PositiveBenzinga•Dec 10, 2025, 02:05 PM
Jaguar Health's Napo Therapeutics Requests Advice From EMA's CVMP Regarding Its Plan To Pursue Approval Of Canalevia In EU For Treatment Of General Diarrhea In Dogs
➖ NeutralBenzinga•Dec 2, 2025, 02:05 PM
Jaguar Health's Napo Pharma Granted Australian Patent For Crofelemer-Based Methods Treating SBS And Bile Acid Diarrhea
📈 PositiveBenzinga•Nov 24, 2025, 02:07 PM
Jaguar Health Submits All Amended Protocol To FDA For Its Current Clinical Studies Of Crofelemer In Pediatric MVID Participants
➖ NeutralBenzinga•Nov 20, 2025, 02:04 PM
Jaguar Health Q3 EPS $(6.28) Misses $(5.08) Estimate, Sales $3.083M Miss $3.730M Estimate
📉 NegativeBenzinga•Nov 17, 2025, 01:04 PM
Jaguar Health To Present An Abstract With Partial Results From An Ongoing Investigator-Initiated Trial Of Crofelemer Demonstrating Disease Progression Modification And Reduction Of Total Parenteral Support In Pediatric Intestinal Failure Patients Ranging Between 12% To 37%
📈 PositiveBenzinga•Nov 6, 2025, 02:09 PM
Jaguar Health Completes Meeting With U.S. Food and Drug Administration For Potential Approval To Treat Pediatric Indication Microvillus Inclusion Disease
📈 PositiveBenzinga•Oct 6, 2025, 01:06 PM
Jaguar Health Files For Resale Of Up To 2.6M Shares By The Selling Stockholders
📉 NegativeBenzinga•Oct 3, 2025, 08:20 PM
Jaguar Health Says On September 28, Co Entered Securities Purchase Agreement With Brown Stone Capital Limited; Purchase Price Of Shares Is $1.56 Per Share
➖ NeutralBenzinga•Oct 1, 2025, 08:22 PM
Jaguar Health Receives Notice Of $250K Grant From FDA's Center For Veterinary Medicine To Support Confirmatory Study For Canalevia-CA1 For Chemotherapy-Induced Diarrhea In Dogs
📈 PositiveBenzinga•Sep 25, 2025, 01:05 PM
Jaguar Health's Napo Pharma Submits Orphan Drug Application To FDA For Crofelemer To Treat Diarrhea In Metastatic Breast Cancer Patients On Targeted Therapy
📈 PositiveBenzinga•Sep 24, 2025, 01:04 PM
Jaguar Health's Canalevia-CA1 Conditionally FDA-Approved For Canine Chemotherapy-Induced Diarrhea; Enrollment Has Reached ~25%; Seeks Partnerships To Expand Indication To General Diarrhea In Dogs
📈 PositiveBenzinga•Aug 21, 2025, 01:05 PM
Jaguar Health's Napo Pharmaceuticals To Discuss Potential Regulatory Pathways With FDA Regarding Crofelemer For Ultrarare Pediatric Indication Microvillus Inclusion Disease
➖ NeutralBenzinga•Aug 19, 2025, 01:02 PM
Jaguar Health prices 0.25M shares at $6.09 in registered direct offering
📉 NegativeSeeking Alpha•May 21, 2025, 12:12 PM
Frequently Asked Questions about JAGX
What is JAGX's current stock price?
Jaguar Health, Inc. (JAGX) is currently trading at $1.17 per share. The stock has moved +3.54% today.
What is the analyst price target for JAGX?
The average analyst price target for JAGX is $12.98, based on 1 analyst.
What sector is Jaguar Health, Inc. in?
Jaguar Health, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is JAGX's market cap?
Jaguar Health, Inc. has a market capitalization of $0.00 billion, making it a small-cap company.
Does JAGX pay dividends?
No, Jaguar Health, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorBDRX
Biodexa Pharmaceuticals Plc
$3.64
Mkt Cap: $0.0B
CANF
Can-Fite BioPharma Ltd.
$0.25
Mkt Cap: $0.0B
CLDI
Calidi Biotherapeutics, Inc.
$1.36
Mkt Cap: $0.0B
CNSP
CNS Pharmaceuticals, Inc.
$6.51
Mkt Cap: $0.0B
GNPX
Genprex, Inc.
$2.13
Mkt Cap: $0.0B
GRI
GRI Bio, Inc.
$0.34
Mkt Cap: $0.0B
INM
InMed Pharmaceuticals Inc.
$1.19
Mkt Cap: $0.0B
KZIA
Kazia Therapeutics Limited
$10.87
Mkt Cap: $0.0B
SILO
Silo Pharma, Inc.
$0.38
Mkt Cap: $0.0B
SXTP
60 Degrees Pharmaceuticals, Inc.
$0.76
Mkt Cap: $0.0B
Explore stocks similar to JAGX for comparison